Smart Material Uses Body’s Own Healing Proteins to Help Repair Wounds

Millions of people worldwide live with wounds that simply won’t heal. Diabetic foot ulcers, severe burns, and fractured bones that refuse to mend cause tremendous suffering, and the treatments available today are costly, imprecise, and sometimes dangerous. Now, researchers have developed a new class of material that doesn’t deliver manufactured drugs at all. Instead, it captures the body’s own growth factors and releases them right where a cell grips the material and pulls, triggered by nothing more than the natural mechanical force of living cells. The work sits at an early, preclinical stage, and significant research remains before any patient use could be considered.

Published in the journal Nature Materials, the study introduces a platform called TrAPs, short for traction-force-activated payloads. This technology uses specially engineered molecular structures that grip growth factors tightly until a cell physically grabs onto the material and pulls. That mechanical tug from the cell itself unlocks the protein and delivers it at the precise point of contact. It follows a fundamentally different logic from currently approved protein-delivery approaches such as topical gels, protein-soaked sponges, and injectable formulations, which deposit growth-promoting proteins into a wound and leave them to drift.

A notable feature emerged in laboratory experiments: TrAP-equipped materials harvested growth factors from platelet lysate derived from human blood and held them in reserve until cells arrived to claim them, all without factory-manufactured proteins. According to the authors, this points toward a future in which a patient’s own blood could serve as the source at the bedside, an application the study did not directly test. If borne out by further research, that capability could ease the refrigeration requirements and regulatory logistics that make conventional protein-based drugs expensive and hard to deploy. The authors carefully describe the work as a proof of concept that needs much larger studies before any conclusions about clinical feasibility can be drawn.

Why Current Wound Treatments Fall Short

When a wound struggles to heal, doctors sometimes apply proteins called growth factors, signaling molecules that tell cells to grow new blood vessels, divide, and migrate into damaged tissue. Several such treatments are already approved, including topical gels, sprays, injections, and protein-soaked sponges, such as Regranex, Fiblast, Heberprot-P, and INFUSE.

Trouble is, these proteins break down within minutes once inside the body. To compensate, clinicians must apply large doses, far more than the body would naturally produce. Doses that far exceed natural levels carry real risks, including uncontrolled tissue growth and, in some cases, abnormal bone formation. The approved bone-repair product INFUSE, for example, delivers roughly 1.4 milligrams of protein per cubic centimeter of implant, a figure the study’s authors cite to illustrate how much lower TrAP doses are. TrAPs, according to the study, operate at doses orders of magnitude below that benchmark.

How TrAPs Actually Work

Each TrAP is a precisely engineered molecular construct attached to a scaffold material; in these experiments, most often a collagen sponge placed directly into a wound. One end of the construct anchors to the scaffold. The other end carries a tiny protein fragment that cells recognize and grab onto using their surface receptors. When a migrating cell pulls on that handle as it moves through the material, the construct physically unfolds and releases the growth factor it was holding.

A key design feature is that the growth factor stays bound and inhibited until cellular forces trigger its release. That approach avoids the constant, uncontrolled flooding of the wound seen with current treatments, where proteins are deposited and left to diffuse. Only a cell that physically engages the material can unlock the protein, and even then, the release happens right at the point of contact.

Construct durability also stood out. Unmodified oligonucleotide aptamers like those used in TrAPs typically break down within minutes to hours once exposed to biological fluids. Yet in this study, the TrAPs kept working across multiple animal species and tissue types long enough to produce measurable biological effects within the experimental window. The authors call this a particularly interesting and unexpected finding with potential relevance for DNA-based medicine, though the study did not establish indefinite stability or complete resistance to degradation.

Testing in Rats, Mice, and Human Tissue

Experiments ran across multiple species and tissue systems to test whether the idea actually works in living tissue, not just in a lab dish.

In a rat bone repair model, collagen sponges loaded with TrAPs designed to capture and release a protein that promotes new blood vessel growth were implanted into a surgically created gap in the thigh bone. After three weeks, the treated bones showed more blood vessels and significantly larger vessels than control groups that received no sponge, a plain sponge, or a sponge carrying a scrambled version of the construct that could not properly deliver the protein. Bone growth itself was not affected over twelve weeks, as expected, because the treatment targeted blood vessel formation rather than bone formation. No major adverse events showed up in any animal in this exploratory study. Because toxicity and immune response were not primary objectives, though, the authors flag dedicated safety assessments as a necessary step for future work before any conclusions about safety can be drawn.

In a mouse skin wound model, collagen sponges carrying a combination of four different TrAPs, designed to harvest multiple growth factors from a protein-rich preparation derived from human blood, were implanted into full-thickness skin wounds. After ten days, wounds treated with the active TrAP sponges showed a meaningful reduction in wound diameter compared with control groups. A trend toward increased new tissue thickness beneath the sponge also appeared.

Human tissue was tested using skin removed from donors undergoing routine procedures and kept alive in laboratory conditions. Wounds created in this tissue and treated with TrAP sponges carrying a combination of three growth factors harvested from human platelet lysate showed significantly better integration between the skin and the sponge material by day eight, compared with most control groups. Cells, including migrating skin cells, were found growing deeper into the wound treatment area. Cross-sections of tissue from the combined TrAP group were also more likely to remain physically intact during laboratory processing, suggesting the treated tissue had formed a more cohesive structure.

All human tissue donors provided informed consent, and the work was conducted under approved ethical frameworks.

What This Could Mean for Hard-to-Treat Wounds

Beyond the specific results, the paper highlights several features that could make the technology practical in real clinical settings if future studies bear out its promise. Because the constructs pull growth factors from blood-derived material, the authors propose that the approach might eventually allow bedside preparation from a patient’s own blood, useful in low-resource settings or field medicine where cold storage is hard to maintain. That application, they stress, remains untested.

Modularity is another selling point. Because TrAPs can, in principle, work with virtually any scaffold material and any growth factor for which a high-affinity aptamer exists, the system could eventually be tailored to many different kinds of tissue damage. More than thirty years of research into such molecular binding structures already exists, giving scientists a large library of potential TrAP configurations to draw on.

Two of the study’s authors have co-founded a company based on this technology, and one holds a patent on it, the authors report openly. The research still needs larger animal studies, toxicity assessments, and eventual clinical trials before anything reaches patients.

For the millions of people whose wounds refuse to heal, a material that stays quiet until living cells pull on it, then releases its protein right at that spot, offers a different way to approach growth-factor treatment. The platform remains preclinical, and much testing lies ahead, but the early results make a solid case for finding out how far it can go.

---